LaFleur & Godfrey LLC boosted its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 64.5% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 133,714 shares of the company's stock after acquiring an additional 52,414 shares during the quarter. LaFleur & Godfrey LLC's holdings in Kenvue were worth $3,206,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. SRS Capital Advisors Inc. boosted its position in Kenvue by 67.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after purchasing an additional 571 shares in the last quarter. Continuum Advisory LLC boosted its position in shares of Kenvue by 2,071.1% in the 1st quarter. Continuum Advisory LLC now owns 1,954 shares of the company's stock worth $47,000 after buying an additional 1,864 shares in the last quarter. Clarity Asset Management Inc. acquired a new stake in Kenvue in the 4th quarter valued at about $45,000. SBI Securities Co. Ltd. purchased a new position in Kenvue during the 4th quarter valued at about $46,000. Finally, Versant Capital Management Inc raised its position in Kenvue by 77.9% during the first quarter. Versant Capital Management Inc now owns 3,415 shares of the company's stock worth $82,000 after acquiring an additional 1,495 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.
Kenvue Trading Down 0.7%
Shares of KVUE traded down $0.16 during mid-day trading on Tuesday, hitting $21.21. The company had a trading volume of 16,637,844 shares, compared to its average volume of 16,255,292. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $25.17. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.63. The business's 50-day simple moving average is $22.96 and its 200-day simple moving average is $22.39. The stock has a market cap of $40.70 billion, a PE ratio of 38.57, a P/E/G ratio of 3.32 and a beta of 0.98.
Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.01. The company had revenue of $3.74 billion during the quarter, compared to analysts' expectations of $3.69 billion. Kenvue had a net margin of 6.90% and a return on equity of 20.87%. The business's quarterly revenue was down 3.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.28 EPS. Sell-side analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.
Kenvue Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th were issued a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, May 14th. This represents a $0.82 annualized dividend and a yield of 3.87%. Kenvue's payout ratio is 149.09%.
Wall Street Analysts Forecast Growth
KVUE has been the subject of a number of recent research reports. Canaccord Genuity Group raised their price objective on shares of Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Piper Sandler raised their price target on Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research report on Monday, February 24th. Redburn Atlantic assumed coverage on Kenvue in a report on Thursday, April 10th. They issued a "neutral" rating and a $23.50 price target for the company. Citigroup reaffirmed a "neutral" rating on shares of Kenvue in a research note on Friday, June 13th. Finally, Barclays boosted their target price on shares of Kenvue from $22.00 to $23.00 and gave the company an "equal weight" rating in a research note on Monday, May 12th. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $25.33.
View Our Latest Stock Analysis on KVUE
Kenvue Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Recommended Stories
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
